ABCB4 and Hepatic fibrosis: To investigate the potential anti-fibrogenic effects of CM414, we used a clinically relevant animal model of chronic portal inflammation and bile duct proliferation with progression to liver fibrosis and cancer (Mdr2/Abcb4-deficient mice (Mdr2-KO)).